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Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of
TB. We investigated costs and yield from systematic HIV-TB screening, including computer-
aided digital chest X-ray (DCXR-CAD).
Methods and findings
In this open, three-arm randomised trial, adults (�18 years) with cough attending acute pri-
mary services in Malawi were randomised (1:1:1) to standard of care (SOC); oral HIV testing
(HIV screening) and linkage to care; or HIV testing and linkage to care plus DCXR-CAD with
sputum Xpert for high CAD4TBv5 scores (HIV-TB screening). Participants and study staff
were not blinded to intervention allocation, but investigator blinding was maintained until
final analysis. The primary outcome was time to TB treatment. Secondary outcomes
included proportion with same-day TB treatment; prevalence of undiagnosed/untreated
bacteriologically confirmed TB on day 56; and undiagnosed/untreated HIV. Analysis was
done on an intention-to-treat basis. Cost-effectiveness analysis used a health-provider per-
spective. Between 15 November 2018 and 27 November 2019, 8,236 were screened for eli-
gibility, with 473, 492, and 497 randomly allocated to SOC, HIV, and HIV-TB screening
arms; 53 (11%), 52 (9%), and 47 (9%) were lost to follow-up, respectively. At 56 days, TB
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treatment had been started in 5 (1.1%) SOC, 8 (1.6%) HIV screening, and 15 (3.0%) HIV-
TB screening participants. Median (IQR) time to TB treatment was 11 (6.5 to 38), 6 (1 to 22),
and 1 (0 to 3) days (hazard ratio for HIV-TB versus SOC: 2.86, 1.04 to 7.87), with same-day
treatment of 0/5 (0%) SOC, 1/8 (12.5%) HIV, and 6/15 (40.0%) HIV-TB screening arm TB
patients (p = 0.03). At day 56, 2 SOC (0.5%), 4 HIV (1.0%), and 2 HIV-TB (0.5%) partici-
pants had undiagnosed microbiologically confirmed TB. HIV screening reduced the propor-
tion with undiagnosed or untreated HIV from 10 (2.7%) in the SOC arm to 2 (0.5%) in the
HIV screening arm (risk ratio [RR]: 0.18, 0.04 to 0.83), and 1 (0.2%) in the HIV-TB screening
arm (RR: 0.09, 0.01 to 0.71). Incremental costs were US$3.58 and US$19.92 per participant
screened for HIV and HIV-TB; the probability of cost-effectiveness at a US$1,200/quality-
adjusted life year (QALY) threshold was 83.9% and 0%. Main limitations were the lower
than anticipated prevalence of TB and short participant follow-up period; cost and quality of
life benefits of this screening approach may accrue over a longer time horizon.
Conclusions
DCXR-CAD with universal HIV screening significantly increased the timeliness and com-
pleteness of HIV and TB diagnosis. If implemented at scale, this has potential to rapidly and




Why was this study done?
• Tuberculosis (TB), one of the leading infectious killers worldwide, remains challenging
to diagnose in low-resource settings, and patients frequently face multiple health centre
visits at high cost before TB is diagnosed and treatment started. HIV is a major risk fac-
tor for TB.
• Robust digital X-ray equipment can now be deployed at a primary care level in sub-
Saharan Africa, and automated computer software packages that can interpret chest X-
rays providing a probabilistic score for pulmonary TB have accuracy similar to, or
greater than, expert human readers.
• We therefore set out to investigate whether offering adults with cough attending pri-
mary care in Blantyre, Malawi universal HIV testing and linkage to antiretroviral ther-
apy (ART)—either alone or combined with computer-aided digital chest X-ray (DCXR-
CAD) and subsequent sputum Xpert confirmation—could improve the timeliness and
completeness of HIV and TB diagnosis and treatment compared to current standard
approaches (health worker–directed TB and HIV screening).
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What did the researchers do and find?
• A total of 1,462 adults attending a primary clinic in Blantyre, Malawi with cough were
randomly allocated to receive either standard of care (SOC) health worker–directed
HIV-TB screening; oral HIV testing and linkage to treatment (HIV screening); or oral
HIV testing and linkage to treatment with additional digital chest X-ray screening for
TB interpreted by computer-aided diagnosis software (CAD4TBv5), with sputum Xpert
testing for participants with a CAD4TBv5 score above 45 (HIV/TB screening). Partici-
pants were followed for 56 days to investigate initiation of TB treatment, missed TB and
HIV diagnosis, and cost-effectiveness.
• Median time to TB treatment initiation was shorter (1 day) in the HIV-TB screening
arm compared to the SOC arm (11 days) and HIV screening arm (6 days). HIV screen-
ing reduced undiagnosed/untreated HIV from 10 (2.7%) in the SOC arm to 2 (0.5%) in
the HIV screening arm and 1 (0.2%) in the HIV-TB screening arm.
• Over the trial follow-up period (56 days), oral HIV testing and linkage to care were
likely to be cost-effective, but digital chest X-ray with computer-aided interpretation
was not.
What do these findings mean?
• Digital chest X-ray screening with computer-aided interpretation for TB with universal
HIV screening increased the timeliness and completeness of HIV and TB diagnosis.
• If implemented at scale, these interventions have the potential to rapidly and efficiently
improve TB and HIV diagnosis and treatment.
Introduction
Despite being a leading infectious cause of adult mortality worldwide [1], tuberculosis (TB)
remains challenging to diagnose, especially in low-resource settings [2]. In sub-Saharan Africa,
where prevalence of active pulmonary TB can exceed 1% in some high HIV prevalence urban
settlements [3], adults with TB symptoms frequently make multiple visits to primary health-
care services before TB testing is initiated [4]. Late and missed TB diagnosis is common, with
severe consequences including hospitalisation, death, ongoing transmission, and catastrophic
household expenditure associated with care-seeking and illness [4,5].
Guidelines recommend that adults attending health facilities be routinely screened for TB
and investigated appropriately if symptomatic [6]. However, only a small percentage of clinic
attenders successfully complete the TB screening cascade due to limited health worker num-
bers, high numbers of patient with symptoms of TB overwhelming testing capacity, and low
availability and high cost of diagnostics [7].
Currently available TB diagnostics are not well suited to primary healthcare, and, conse-
quently, patients are most likely to be lost during the diagnostic phase. Sputum smear micros-
copy has low sensitivity and is resource intensive [8]; Xpert—although more sensitive,
especially for HIV–positive people [9,10]—is costly, and throughput is constrained by unit
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capacity [11]; lateral flow urine lipoarabinomannan assay (LF-LAM) is not currently recom-
mended for HIV–negative people or HIV–positive outpatients without advanced immunosup-
pression [12]; and sputum mycobacterial culture remains costly, slow, and inaccessible to most
primary clinics. Offering newer TB diagnostics such as Xpert to all adult primary clinic attend-
ers with symptoms of TB (which can approach 60% [7]) could rapidly overwhelm clinic testing
capacity and health systems’ budgets.
Rapid advances in digital X-ray technologies linked to computer-aided chest X-ray inter-
pretation (DCXR-CAD) [13,14] mean that a “triage testing” approach to TB screening in pri-
mary care could remove barriers to high coverage of same-day, same-clinic TB diagnosis and
treatment [15]. Digital chest X-ray provides a high-sensitivity and high-throughput initial
screen for individuals with symptoms of TB [16], while computer-aided interpretation—soft-
ware algorithms that provide an immediate probabilistic score for TB—remove the need for
trained interpreters [17,18]. As specificity of chest X-ray for pulmonary TB is low, a positive
X-ray triage screen should be confirmed with a high-specificity diagnostic test such as Xpert.
Triage testing with DCXR-CAD could then substantially reduce the number of expensive
Xpert tests that would have otherwise been required [19]. WHO has recently recommended
that DCXR-CAD can be used for TB screening [18], but the impact on patient outcomes is
unknown.
In this three-arm pragmatic randomised trial conducted in primary care in urban Blantyre,
Malawi, we investigated whether a universal HIV testing and linkage to antiretroviral therapy
(ART) intervention—either alone or combined with DCXR-CAD and subsequent sputum
Xpert confirmation—could improve the timeliness and completeness of HIV and TB diagnosis
and treatment. We additionally evaluated cost-effectiveness of implementation.
Methods
Study design
We conducted a three-arm, open, pragmatic randomised trial among adults recruited from an
urban primary healthcare clinic in Blantyre, Malawi [20] (S1 Text). Bangwe Health Centre is
located within a densely populated neighbourhood in the east of the city. Adult HIV preva-
lence in Blantyre is estimated to be 18% [21], and Malawi urban TB prevalence was estimated
at 988 per 100,000 in the most recent national TB prevalence survey [22]. Comprehensive HIV
care (including ART) and TB treatment are available at a primary care level through the
national HIV and TB treatment programmes in Malawi.
All Blantyre-resident adults (�18 years old) attending Bangwe Health Centre acute depart-
ment who reported cough of any duration were eligible to participate and were screened for
eligibility by study research assistants (6 in total, not medically trained, but with experience in
community and clinic-based research) at the clinic registration desk. We excluded individuals
who had taken TB treatment in the preceding 6 months, who were currently taking TB preven-
tive therapy, or who planned to move out of Blantyre. All participants gave written (or, if illit-
erate, witnessed thumbprint) informed consent to participate. Ethical approval was granted by
the College of Medicine, University of Malawi Research Ethics Committee, and the Liverpool
School of Tropical Medicine.
Randomisation and masking
Participants were individually randomised without restriction to 1 of 3 arms—standard of care
(SOC), HIV screening, or HIV-TB screening—in a 1:1:1 ratio using a computer-generated
random number sequence running on study data collection electronic devices. Because of the
nature of interventions, it was not possible to blind participants or study teams to allocation.
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However, investigator masking was maintained until after final statistical analysis. To mini-
mise the risk of contamination between arms, a digital thumbprint (Simprints, Cambridge,
United Kingdom) was recorded at recruitment and used to validate identity.
Procedures
All participants underwent a baseline questionnaire by study research assistants, conducted in
a dedicated study research building within the grounds of the clinic.
Participants allocated to the SOC arm were directed to the clinic acute waiting area, where
they were managed by clinic health workers without any further input from study staff. As this
was a pragmatic trial, we intended that the SOC arm procedures would reflect the routine TB
and HIV screening care delivered by a typical Ministry of Health primary care clinic in a low-
resource setting. Available to participants in the SOC arm (if requested by a clinic health
worker) were the following: sputum smear microscopy; sputum Xpert, TB treatment; HIV test-
ing using rapid fingerprick diagnosis kits; and ART, as well as other routine primary health
services. Malawi National Guidelines recommend HIV testing for all adults attending health
facilities, although this is often not completed [23]. Clinic health workers included nurses, clin-
ical officers, and HIV counsellors employed by the Ministry of Health of Malawi, but no
physicians.
Participants allocated to the HIV screening arm who self-reported being HIV negative,
or HIV positive but not taking ART, were offered HIV testing using oral kits (OraQuick
HIV 1/2 Rapid Antibody Test, OraSureAU : PleaseprovidemanufacturerlocationdetailsforOraSureandTrinityBiotechinthesentenceParticipantsallocatedtotheHIVscreeningarmwhoself   reported:::Technologies, Manuf ctured in Thailand), with
confirmatory testing using serial testing with rapid kits (Determine HIV-1/2, Alere,
Japan; Uni-gold HIV, Trinity Biotech, Ireland). HIV–positive participants were sup-
ported to register for ART at the onsite clinic by walking with them to the ART clinic reg-
istration area and making an appointment for treatment initiation assessment by the
ART clinic staff (in practice usually done on the same day, in accordance with Malawi
guidelines). Further investigations and management, including TB investigations, were
provided by clinic health workers in accordance with national guidelines without any
further input from study staff.
In addition to the HIV testing intervention, participants in the HIV-TB screening arm
were offered a single posterior–anterior digital chest X-ray (MinXray Commander CMDR.
T.120.60. S, United States of America) done by study radiographers with interpretation
using CAD4TB v5 (Delft Imaging, the Netherlands). CAD4TB interpretation was done
locally on a dedicated computer, with results automatically transferred to study data collec-
tion devices. Where the CAD4TB score was �45 (threshold selected based on pilot studies
and in discussion with the software developer), participants’ sputum was tested onsite by
Xpert; if positive, they were initiated on TB treatment by the clinic TB officer. Where the
Xpert was negative or CAD4TB score was <45, they were directed to the clinic waiting area
for further management by clinic health workers. Digital chest X-rays were additionally
read remotely by a consultant radiologist, and participants with abnormal findings identi-
fied were recalled by telephone and referred to the clinic or city central hospital with
results.
Participants were seen at the study clinic at 56 days, when they underwent questionnaire
and inspection of health records to determine TB treatment status, HIV testing (if not known
to be HIV positive and taking ART) and sputum collection for Xpert, MGIT culture and
smear, with samples analysed at the TB Research Laboratory at the College of Medicine, Uni-
versity of Malawi. Participants who did not attend the clinic for this outcome assessment were
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traced to home, where possible. Loss to follow-up was defined as participants who did not
attend their clinic day 56 outcome assessment appointment and could not be traced to home.
Outcomes
The primary outcome was time in days—up to, but not including, day 56—to TB treatment
initiation. Secondary outcomes were the proportion of participants with same-day TB treat-
ment initiation; proportion of participants with undiagnosed/untreated microbiologically con-
firmed pulmonary TB on day 56 (either sputum culture, or sputum Xpert, or sputum smear
microscopy positive on day 56 sample); proportion with undiagnosed/untreated HIV; time in
days—up to, but not including, day 56—to ART initiation among participants with positive
confirmatory HIV test results at day 56 and who were not taking ART at day 0; mortality; and
quality of life (assessed by difference in EuroQoL EQ5D utility score, a continuous variable
that can take values between less than 0 and 1).
Statistical analysis
The statistical power was estimated for the primary outcome under the assumption that 17%
of adults with TB symptoms in primary care in Blantyre would initiate TB treatment by 56
days [24] (S2 Text). A sample size of 1,455 participants (485 per arm) gave at least 80% power
to detect a hazard ratio (HR) for TB treatment initiation of 1.5 comparing the HIV screening
arm to SOC, a HR of 1.5 comparing HIV-TB screening arm to SOC, and a HR of 1.41 compar-
ing the HIV-TB screening arm to HIV screening arm, at 5% significance level, allowing for 5%
loss to follow-up and with no adjustment for multiplicity of testing.
This study is reported as per the Consolidated Standards of Reporting Trials (CONSORT)
guideline (S3 Text). We performed analysis according to the intention to treat principle. To
maintain investigator blinding, no inspection of data by trial arm was done until data cleaning
was complete and the database locked; the trial statistician then undertook unblinded analysis
of the locked trial database. Data are deposited in the Dryad repository doi: 10.5061/dryad.
ffbg79ctb [25]. Baseline characteristics were summarised for the 3 trial arms using proportions,
means (with standard deviations), and medians (with interquartile ranges (IQRs)). For analysis
of the primary outcome, we compared survival times using log-rank tests and constructed Cox
proportional hazard regression models to estimate HRs and 95% confidence intervals (CIs) for
each pairwise comparison between arms. Participants lost to follow-up were censored at the
last point of contact. Log–log plots were examined and tests of Schoenfeld residuals conducted
to check the proportional hazards assumption. To analyse binary secondary outcomes (pro-
portion with same-day TB treatment initiation, proportion with undiagnosed/untreated pul-
monary TB, proportion with undiagnosed/untreated HIV, and proportion reported to have
died), we constructed binomial regression models with a log link function to estimate relative
risk ratios (RRs) and 95% CIs, comparing between pairs of arms. To evaluate the effect of
interventions on health-related quality of life, we used linear regression to compare the mean
EQ5D utility scores measured at day 56 between pairs of arms, adjusting for participants’ cor-
responding values measured at baseline. Residual plots were examined to check linear regres-
sion assumptions. For secondary outcomes with missing data, sensitivity analysis was
conducted using multiple imputation with chained equations and 50 imputations.
Cost-effectiveness analysis
Cost–utility analysis was undertaken to estimate the incremental cost per quality-adjusted life
year (QALY) gained from the Malawian Ministry of Health perspective (S4 Text). Question-
naires captured the health resources utilised by participants over the trial time horizon. This
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included any additional care received in hospitals and primary health clinics. Participant
responses to the Chichewa version of the EQ-5D-3L were used to generate health utility scores
and QALY profiles [26–28]. Incremental cost-effectiveness ratios (ICERs) were estimated to
compare the 2 intervention arms to the SOC arm. Malawi does not have formal cost-effective-
ness thresholds. We therefore compared the estimated ICERs to WHO-recommended thresh-
olds using the gross domestic product (GDP) per capita for the country. Interventions that
have an incremental cost per gain in QALY less than the national GDP per capita were defined
as "very cost-effective," and those less than 3 times GDP per capita as "cost effective" [29]. The
GDP per capital of Malawi is approximately US$400 per capital. WeAU : PleasecheckandconfirmthattheeditstothesentenceWethereforeused1; 000bootstrappedreplicationstopresentthatthe:::didnotaltertheintendedthoughtofthesentence:therefore used 1,000 b ot-
strapped replications to present the probability of the 2 interventions (HIV screening and
HIV-TB screening) being cost-effective at increasing cost-effectiveness thresholds: US$400/
QALY, US$800/QALY, and US$1,200/QALY. The probability represents the proportion of the
1,000 bootstrapped replications where the estimated ICER was below these cost-effectiveness
thresholds. This analysis is reported as per the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) guideline [30] (S5 Text).
Results
Between 15 November 2018 and 22 November 2019, 8,236 patients were screened, of whom
1,462 were randomly allocated to the SOC (473), HIV screening (492), or HIV-TB screening
(497) arms (Fig 1). One participant withdrew consent after baseline interview, but before
randomisation.
Fig 1. Trial profile. IPTAU : AbbreviationlistshavebeencompiledforthoseusedinFigs1   3:Pleaseverifythatallentriesarecorrect:, isoniazid preventive t erapy; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003752.g001
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Characteristics of participants were balanced between arms (Table 1). Over half of partici-
pants were women in each arm, and mean ages ranged from 33 to 34 years old. Symptoms indic-
ative of TB were common, with 40% to 43% reporting night sweats, 38% to 41% reporting
Table 1. Participant characteristics.
Characteristic SOC arm (n = 473) HIV screening arm (n = 492) HIV-TB screening arm (n = 497)
Age in years (mean, SD) 33.5 (13.5) 32.8 (13.4) 34.3 (13.4)
Sex
Male (n, %) 208 (44%) 196 (40%) 228 (46%)
Female (n, %) 265 (56%) 296 (60%) 269 (54%)
Body mass index (mean kg/m2, SD) 22.8 (4.1) 22.7 (4.3) 22.9 (4.5)
Marital status
Married/cohabiting (n, %) 322 (68%) 347 (71%) 330 (66%)
Never married (n, %) 76 (16%) 74 (15%) 82 (16%)
Widowed/separated/divorced (n, %) 74 (16%) 71 (14%) 85 (17%)
Highest level of education
No schooling (n, %) 59 (12%) 59 (12%) 61 (12%)
Primary (n, %) 217 (46%) 234 (48%) 234 (47%)
Secondary no MSCE† (n, %) 130 (27%) 131 (27%) 125 (25%)
Secondary with MSCE† (n, %) 60 (13%) 56 (11%) 70 (14%)
Higher (n, %) 7 (1%) 12 (2%) 7 (1%)
Ever lost a spouse to death 44 (9%) 40 (8%) 46 (9%)
Literate 405 (86%) 426 (87%) 425 (86%)
Poverty quintileø
uintile 1 (least poor) 94 (20%) 99 (20%) 99 (20%)
Quintile 2 99 (21%) 106 (22%) 87 (18%)
Quintile 3 84 (18%) 102 (21%) 107 (22%)
Quintile 4 106 (22%) 90 (18%) 96 (19%)
Quintile 5 (poorest) 90 (19%) 95 (19%) 108 (22%)
TB symptoms
Cough (n %) 473 (100%) 492 (100%) 497 (100%)
Cough duration (median weeks, IQR) 1 (0.6, 2) 1 (0.4, 3) 1 (0.4, 3)
Night sweats (n, %) 203 (43%) 197 (40%) 200 (40%)
Weight loss (n, %) 194 (41%) 186 (38%) 195 (39%)
Fever (n, %) 242 (51%) 253 (51%) 250 (50%)
Previously treated for TB (n %) 17 (4%) 21 (4%) 26 (5%)
HIV status
HIV–positive (n, %) 86 (18%) 93 (19%) 101 (20%)
Taking ART (n, %) 82 (95%) 90 (97%) 99 (98%)
HIV–negative (n, %) 354 (75%) 365 (74%) 355 (71%)
Unknown (n, %) 33 (7%) 34 (7%) 41 (8%)
EQ5D§ utility score (mean, SD) 0.79 (0.14) 0.77 (0.15) 0.77 (0.14)
Self-rated health
Fair/good/very good 412 (87%) 440 (89%) 444 (89%)
Poor/very poor 61 (13%) 52 (11%) 53 (11%)
†Malawi Secondary Certificate of Education.
øBased on urban proxy means test using assets derived from 2014–2015 Malawi Integrated Household Survey.
§EuroQOL EQ5D utility score (Zimbabwe tariff).
ARTAU : TheabbreviationlistsinTables1   3havebeenupdated:Pleaseverifythatallentriesarecorrect:, antiretroviral ther py; IQR, interquartile range; SD, standard deviation; SOC, stand rd of care; TB, tub rculosis.
https://doi.org/10.1371/journal.pmed.1003752.t001
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weight loss, and 50% to 51% reporting fever. Between 4% and 5% of participants reported having
been previously treated for TB. Knowledge of HIV status was very high (over 90%), with 18%,
19%, and 20% of participants in the SOC, HIV, and HIV-TB screening arms, respectively, self-
reporting HIV–positive status. ART coverage was also very high at 95%, 97%, and 98%.
In the HIV-TB screening arm, 448 (90%) participants completed DCXR-CAD, of whom
305 (68%) had a CAD4TB score above the threshold of�45. CAD4TBv5 scores were similar
when compared by participant characteristics (Fig 2A–2E). Of these, 279 (91%) successfully
completed sputum Xpert examination. Approximately 4% (12/279) had TB confirmed on this
initial sample, all of whom subsequently initiated TB treatment. CAD4TBv5 scores were higher
among participants with Xpert-confirmed TB compared to participants with sputum-negative
Xpert tests (Fig 2F). One further participant in the HIV-TB screening arm initiated TB treat-
ment on day 48 with a positive Xpert result from the routine health system.
Of the 399 participants in the HIV screening arm and 396 participants in the HIV-TB
screening arm who reported never having previously tested for HIV or being HIV negative,
336 (84%) and 362 (91%), respectively, received study HIV testing on the same day. A total of
1,320 (90%) participants had day 56 vital status ascertained, with similar proportions in all 3
arms (SOC: 420/473 [89%], HIV screening: 450/492 [91%], and HIV-TB screening: 450/497
[91%]), and 1,206 (82%) had day 56 TB/HIV outcomes ascertained (Fig 1). Participants lost to
follow-up were slightly younger on average than those seen at day 56 and more likely to report
unknown HIV status; otherwise characteristics were comparable (S1 Table).
A greater percentage of participants in the HIV-TB screening arm (15, 3.0%, 95% CI: 1.7%
to 4.9%) initiated TB treatment by day 56 compared to participants in the HIV screening arm
(8, 1.6%, 95% CI: 0.7% to 3.2%) or SOC (5, 1.1%, 95% CI: 0.3% to 2.4%) (Table 2), although
this trend was not statistically significant.
There was a statistically significant increased rate of TB treatment initiation among partici-
pants in the HIV-TB arm compared to SOC (HR: 2.86, 95% CI: 1.04 to 7.87, p = 0.04), but not
for comparisons between other pairs of arms (Fig 3). Overall, 60%, 100%, and 100% of
Fig 2. CAD4TBv5 scores by participant characteristics (HIV-TB screening arm only). ART, antiretroviral therapy;
TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003752.g002
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participants who initiated TB treatment in the SOC, HIV, and HIV-TB screening arms, respec-
tively, had microbiologically confirmed disease at TB treatment initiation. In the HIV-TB arm,
6/15 (40%) of participants treated for TB achieved same-day treatment initiation, compared to
0/5 (0%) in SOC and 1/8 (12.5%) in the HIV screening arm (Fisher’s exact p = 0.03). At day 56
assessment, 2/382 (0.5%), 4/414 (1.0%), and 2/410 (0.5%) in the SOC, HIV, and HIV-TB
screening arms, respectively, had previously undiagnosed or untreated microbiologically con-
firmed TB (RR for HIV-TB arm versus SOC: 0.93, 95% CI: 0.13 to 6.58, p = 0.94).
Only 1/415 (0.2%) participants in the HIV-TB arm who underwent HIV testing at day 56
assessment had previously undiagnosed/untreated HIV infection, compared to 10/377 (2.7%)
in the SOC arm and 2/414 (0.5%) in the HIV screening arm (RR for HIV-TB arm versus SOC:
0.09, 95% CI: 0.01 to 0.71, p = 0.02; RR for HIV arm versus SOC: 0.18, 95% CI: 0.04 to 0.83,
p = 0.03). Of the 20, 25, and 15 participants newly diagnosed with HIV in the SOC, HIV, and
HIV-TB screening arms over the course of the study (including at the day 56 assessment), 6
(30%), 15 (60%), and 9 (60%) initiated ART before day 56, with a median (IQR) number of
days to ART initiation of 5 days (1 to 36), 0 days (0 to 0), and 0 days (0 to 17). There were no
significant differences between pairs of arms in all-cause mortality by day 56. A sensitivity
analysis using multiple imputation to impute missing data for secondary outcomes found sim-
ilar results to the primary analysis (S2 Table).
Mean EuroQoL EQ5D utility scores at day 56 were significantly higher in participants in
the HIV-TB arm compared to SOC (adjusted mean difference [AMD]: 0.03, 95% CI: 0.004 to
0.06, p = 0.02), and in participants in the HIV screening arm compared to SOC (AMD: 0.03,
95% CI: 0.01 to 0.05, p = 0.01). If these differences were maintained for 1 year, at the popula-
tion level, this would result in 3,000 QALYs gained per 100,000 people.
In the base–case analysis, the ICER for the HIV screening arm versus SOC was US$901.29
per QALY gained, and the ICER for HIV-TB screening versus SOC was US$4,620.47 per
Table 2. Effect of interventions on trial outcomes.










Primary outcomes HR, 95% CI HR, 95% CI HR, 95% CI
Number initiating TB treatment (n, %) 5 (1.1%) 8 (1.6%) 15 (3.0%)




6 (1–22) 1 (0–3) 1.51 (0.49–4.62) 1.89 (0.80–4.46) 2.86 (1.04–7.87)
Secondary outcomes RR, 95% CI RR, 95% CI RR, 95% CI
Undiagnosed/untreated microbiologically
confirmed pulmonary TB (n, %)
2/382
(0.5%)
4/414 (1.0%) 2/410 (0.5%) 1.85 (0.34–10.02) 0.50 (0.09–2.74) 0.93 (0.13–6.58)
Same-day TB treatment initiation (n/N, %) 0 (0%) 1 (0.2%) 6 (1.2%) – – –
Undiagnosed/untreated HIV (n, %) 10/377
(2.7%)
2/414 (0.5%) 1/415 (0.2%) 0.18 (0.04–0.83) 0.50 (0.05–5.48) 0.09 (0.01–0.71)
Mortality (n/N, %, OR, 95% CI) 3/420
(0.7%)
3/450 (0.7%) 4/450 (0.9%) 0.93 (0.19–4.60) 1.33 (0.30–5.92) 1.24 (0.28–5.53)
AMD (95% CI)† AMD (95% CI)† AMD (95% CI)†
EQ5D§ utility score (mean, SD) 0.79
(0.18)
0.82 (0.19) 0.81 (0.18) 0.03 (0.004–0.05) −0.003 (−0.03–0.02) 0.02 (0.002–0.05)
0.03 (0.01–0.05) −0.002 (−0.03–0.02) 0.03 (0.004–0.06)
†First row shows unadjusted results; second row shows results adjusted for baseline EuroQoL EQ5D utility score.
§EuroQoL EQ5D utility score (Zimbabwe tariff).
AMD, average mean difference; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; OR, odds ratio; RR, risk ratio; SD, standard deviation; SOC, standard
of care; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003752.t002
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QALY gained (Table 3). At the cost-effectiveness thresholds of US$400, US$800, and US
$1,200 per QALY, the probability of cost-effectiveness for HIV screening was 3.0%, 36.2%, and
83.9%, respectively. Across all these 3 cost-effectiveness thresholds, the probability of cost-
effectiveness for HIV-TB screening was 0%.
Discussion
We have shown that the yield of HIV and TB among symptomatic adults attending primary
care in Malawi was higher and that the time to TB treatment initiation was significantly shorter
where participants received oral HIV testing plus DXCR-CAD TB screening with Xpert con-
firmation compared to clinician-directed TB/HIV screening. Although computer-aided TB
diagnosis was not cost-effective over 8 weeks in the within-trial analysis, participant quality of
life was significantly improved, and further economic analysis over longer time horizons is
required. Universal offer of oral HIV testing was cost-effective and could offer substantial indi-
vidual and public health benefits, even in settings like Malawi where UNAIDS 90–90–90 tar-
gets are close to being met [31]. If implemented at scale in primary care, DCXR-CAD
combined with oral HIV screening has potential to improve diagnosis and treatment of symp-
tomatic TB and HIV among persons presenting to the health facility with cough.
Fig 3. Time to initiation of TB treatment by trial arm. TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003752.g003
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Diagnosis of TB in high HIV-TB burden and low-resource settings is extremely challeng-
ing. Under current recommendations, all clinic attendees should be asked about TB symp-
toms, interpreted according to HIV status, and followed by sputum testing with Xpert or
microscopy of those with symptoms [6,32]. However, with nearly 60% of unselected acute care
clinic attendees reporting TB symptoms [7], the current recommended screening approach for
TB is not reliably implemented, reflecting workload, turnaround time, affordability, and
throughput issues for sputum-based diagnostics. In the absence of an accurate, point-of-care
diagnostic test for TB [33], alternative diagnostic algorithms that reduce demand for sputum-
based diagnostics offer substantial potential benefits. For DCXR-CAD, these include minimal
consumables, high patient throughput, and highly sensitive results available in minutes allow-
ing large numbers to be screened for TB [34]. If DXCR-CAD accuracy is sufficiently high,
there are potential cost-savings and infection control benefits from reducing workload and
demand for sputum tests, as well as other clinical benefits from DCXR-CAD, including rapid
screening for COVID-19 [35]. However, implementation of DCXR-CAD in high HIV/TB bur-
den settings where they are most needed can be challenging and requires careful consideration
by Ministries of Health, as well as technological optimisation for low-resource settings and
operational research to support deployment. Particular challenges can include absent or inter-
mittent power supplies, limited internet availability, availability of maintenance and servicing


















SOC 21.45 (3.18) 0.001 (0.002)
HIV screening 24.29 (1.61) 3.58 (1.70, 5.45) 0.007 (0.002) 0.004 (0.003, 0.005) 901.29 0.030 0.362 0.839
HIV-TB
screening
41.01 (1.17) 19.92 (18.17, 21.68) 0.007 (0.002) 0.004 (0.003, 0.005) 4,620.47 0 0 0
Sensitivity analysis—Imputed data using UK Tarif to derive EQ-5D utility scores#
SOC 21.45 (3.18) 0.001 (0.003)
HIV screening 24.29 (1.61) 3.58 (1.70, 5.45) 0.010 (0.002) 0.005 (0.004, 0.007) 714.69 0.062 0.652 0.959
HIV-TB
screening
41.01 (1.17) 19.92 (18.17, 21.68) 0.009 (0.002) 0.005 (0.004, 0.007) 3,841.67 0 0 0
Sensitivity analysis—Complete cases#
SOC 20.19 (2.77) 0.001 (0.001)
HIV screening 23.72 (1.31) 3.91 (−2.72, 10.53) 0.007 (0.002) 0.004 (0.0005, 0.008) 953.85 0.266 0.445 0.595
HIV-TB
screening
40.33 (0.91) 19.94 (13.50, 26.38) 0.007 (0.002) 0.005 (0.001, 0.009) 4,139.92 0.007 0.008 0.09
Sensitivity analysis—Imputed data using lower cost for digital CXR (US$5)�#
SOC 21.11 (2.95) 0.001 (0.002)
HIV screening 24.16 (1.42) 3.57 (1.72, 5.41) 0.007 (0.002) 0.004 (0.003, 0.005) 961.12 0.020 0.292 0.748
HIV-TB
screening
35.56 (1.09) 14.53 (12.74, 16.32) 0.007 (0.002) 0.004 (0.003, 0.005) 3,600.37 0 0 0
†Incremental estimates are in comparison to SOC arm.
#Adjusted for age, sex, marital status, highest level of education, employment status, and poverty quintile.
Bootstrapped differences (1,000 replications).
�In base–case analysis cost of digital CXR US$10.98.
CrI, credible interval; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SE: standard error, SOC, standard of care; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003752.t003
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personnel, and laboratory capacity to handle potential increased sputum specimen samples for
confirmatory testing, although these were all overcome in this trial.
Here, we investigated “triage testing” adults with cough using automated DCXR-CAD
screening accepting a CAD4TB score cutoff that provided high sensitivity (but correspond-
ingly low specificity) combined with highly specific sputum Xpert confirmation. We achieved
our aim of increasing speed and completeness of TB diagnosis in patients with cough of any
duration but still required sputum from 61% (305/497) participants, a proportion that would
have been similar to that in the SOC arm had national algorithms been consistently applied,
emphasising the need to further optimise DCXR-CAD thresholds for confirmatory testing.
Potential approaches to further reducing sputum test demand include increasing the
CAD4TB score used to define presumptive TB, or adding in a further rapid screening step
such as point-of-care C-reactive protein, or clinical risk prediction scores [36,37]. These
should be implemented and evaluated in conjunction with health system and laboratory
strengthening. DCXR-CAD screening software is rapidly evolving, exceeding expert radiologi-
cal reference standards across a range of target diseases and use-cases [35,38]. However, evi-
dence for health impact or cost-effectiveness under route programmatic conditions—arguably
of greatest importance to health planners—is extremely limited. Moreover, data from low-
resource settings, where computer-aided systems could have greatest benefit in overcoming
limited health worker capacity, are scarce. The CAD4TBv6 system has reported sensitivity of
91% and specificity of 84% compared to sputum Xpert [17], performing significantly better
than expert radiologists and meeting target product profiles for a community TB screening
test [39]. Important questions include the extent to which performance of DCXR-CAD sys-
tems varies by level of health system and patient characteristics such as sex, age, HIV status,
disease stage, and epidemiological setting. As DCXR-CAD costs fall and systems develop,
implementation research will still be needed to evaluate and optimise accuracy and ensure
equity in access to care and health benefits.
Our effectiveness and cost-effectiveness estimates need to be considered in the context of
low levels of investigation for HIV and TB seen in the SOC arm. For example, higher utilisa-
tion of routine clinic HIV testing and less accurate TB sputum screening in the SOC arm
would reduce the likelihood that the HIV screening arm was cost-effective but may conversely
increase the likelihood that offering more accurate TB screening with DCXR-CAD would be
cost-effective. Our economic analysis demonstrates that optimisation of this TB triage testing
approach may be possible. We are undertaking further modelling to evaluate the impact of
lowering DCXR-CAD implementation and running costs; refinement of CAD thresholds to
reduce the number of confirmatory sputum Xpert tests conducted (the major cost-driver
here), while maintaining low false negativity rates in settings with varying pretest TB probabili-
ties; alternative TB confirmatory tests that maintain high specificity and capability to be imple-
mented in low-resource settings; and task-shifting to allow DCXR-CAD scale-up where
radiographers are scarce or not available. Importantly, although CAD thresholds would ideally
be adapted to local epidemiological characteristics and available resources, the large numbers
of participants required and cost of undertaking diagnostic accuracy studies often precludes
this, as in this trial. To minimise the need for multiple diagnostic accuracy studies with micro-
biological reference standards prior to implementation, modelling of accuracy at varying
thresholds—as well as repeated surveillance and threshold adaption under programmatic con-
ditions—will be required.
Malawi, similar to many countries in sub-Saharan Africa, has made tremendous progress in
increasing access to HIV testing and treatment [21]. In this trial conducted in a busy urban
neighbourhood of Blantyre, where adult HIV prevalence approaches 20% [21], greater than
90% of participants reported knowing their HIV status at recruitment, and>95% of HIV–
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positive participants were taking ART. Modelling data suggests that where very high levels of
population ART coverage are achieved, TB incidence will rapidly decline [40]. When planning
this study, we assumed that 17% of participants would initiate TB treatment by 56 days based
on data from a previous study [24]. However, we found TB treatment initiations and preva-
lence of microbiologically confirmed TB to be substantially lower than expected. We speculate,
based on accelerated declines in Blantyre TB case notifications in our citywide TB surveillance
system and from prevalence survey data, that public health interventions such as HIV testing
and universal treatment, active case finding for TB, and scale-up of isoniazid preventive ther-
apy may have caused this reduction. We did not estimate the diagnostic accuracy of
DCXR-CAD, as baseline sputum samples were not collected from participants with a low
CAD4TB score; if DCXR-CAD is widely implemented, surveillance of accuracy at
DCXR-CAD thresholds using microbiological and clinical reference standards should be part
of routine monitoring and evaluation activities. Nevertheless, the substantial individual and
public health benefits offered by routine HIV testing of adults attending primary care with TB
symptoms—even in a setting such as Malawi where HIV testing and treatment are extremely
high—demonstrates that this should remain a central pillar of primary healthcare in countries
with generalised HIV epidemics.
There were a number of limitations to this trial. In this pragmatic trial, alternative diagnoses
to TB were not investigated, with participants referred to routine clinic or hospital care as
required. If DCXR-CAD is widely implemented, clear clinical pathways for people who have
an abnormal CAD4TB score, but who are sputum Xpert negative, will be required [41].
Although more participants initiated TB treatment in the HIV-TB screening arm compared to
the other arms, the proportion with undiagnosed TB was similar across arms. It is not clear
why this is the case but may be due to chance with small numbers of events here. We had
planned subgroup analyses to investigate whether the effects of interventions differed by sex,
an important determinant of delayed TB care-seeking. However, the fewer-than-expected
number of events precluded this and also resulted in a loss of precision in treatment estimates.
This means that our findings may not be robust to any differential missingness between
groups. However, loss to follow-up was similar between arms, and characteristics of partici-
pants followed up were similar to those lost to follow-up. Some participants who were lost to
follow-up may have died. We took extensive measures to limit contamination between arms
(including fingerprint verification of all participants before randomisation, delivery of inter-
ventions, and at follow-up) and to avoid modifying health worker behaviour in the study
clinic, but it is possible that the study presence in the clinic may have modified usual care prac-
tices. Future trials of DCXR-CAD may consider cluster randomisation at the clinic level to
reduce these risks and to potentially increase the number of events observed. For safety rea-
sons, remote radiologists (not usually available in similar primary care settings) provided a
clinical interpretation of chest X-rays, although, given the very short median time to TB treat-
ment initiation, this did not seem to influence TB treatment starts. Malawi has achieved very
high levels of HIV testing and ART coverage; the effectiveness of these interventions should be
evaluated in other settings.
In summary, DCXR-CAD with universal HIV testing for adults attending primary care
with symptoms of TB increased TB diagnoses, shortened time to TB treatment, and was cost-
effective at reducing undiagnosed HIV infection. If effective in larger trials and under pro-
grammatic conditions, this approach has potential to improve diagnosis and treatment of TB
and HIV.
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